Here are four things to know about the transaction and the company’s stock:
• The shares were sold at an average price of $16.46, for a total value of $196,828.
• Following the transaction, Mr. Pierce now directly owns 28,161 shares of the company’s stock, valued at approximately $463,530.
• The company has an average rating of “buy” and an average target price of $15.63.
• Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.71.
More articles on GI/endoscopy:
APIC, SHEA address infections linked to duodenscopes
Wisconsin Economic Development Corp. grants Exact Sciences $9M incentive to create 750 jobs
Capsule endoscopy company Check-Cap closes IPO, simultaneous private placement
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
